Kristin Bierhup
Family · Gallipolis, OHNPI 1477979508
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,566 of the $18,396 with a category attached, or 84.6%. Novo Nordisk accounts for 88.7% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2021 at $9,959 and has fallen 91.5% since, to $846 in 2025. Among family clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 120 payments — averaging $153.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$16K
- Dexcom, Inc.$505
- AstraZeneca$348
- Bayer$342
- AbbVie$118
- Medtronic$103
- plus $669 from 15 others
What the payments were for
- Speaking & faculty fees$15,56685%
- Travel & lodging$1871%
- Food & beverage$2,64414%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 33 | $16,311 |
| Dexcom, Inc. | 26 | $505 |
| AstraZeneca | 7 | $348 |
| Bayer | 16 | $342 |
| AbbVie | 1 | $118 |
| Medtronic | 3 | $103 |
| Lilly USA, LLC | 6 | $94 |
| Cequr Corporation | 2 | $89 |
| Boehringer Ingelheim | 4 | $80 |
| BETA Bionics, Inc. | 5 | $78 |
| Insulet Corporation | 4 | $72 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Abbott | 2 | $38 |
| Tandem Diabetes Care, Inc. | 2 | $34 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Corcept Therapeutics | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| RGH Enterprises LLC | 1 | $20 |
| Mannkind Corporation | 1 | $19 |
| Chiesi USA, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,396 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 69 | $90,012 |
| OzempicSemaglutide | 49 | $58,159 |
| Humalog Kwikpen U-200Insulin Lispro | 16 | $56,997 |
| JardianceEmpagliflozin | 71 | $53,395 |
| TrulicityDulaglutide | 30 | $42,833 |
| Tresiba Flextouch U-200Insulin Degludec | 44 | $40,003 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 34 | $36,737 |
| FarxigaDapagliflozin Propanediol | 25 | $29,169 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 12 | $28,767 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $26,937 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 18 | $26,613 |
| MounjaroTirzepatide | 20 | $21,333 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $14,563 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 25 | $5,915 |
| V-Go 30Sub-Q Insulin Device, 30 Unit | 12 | $5,562 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskXultophy 100-3.6, Ozempic | $16,311 | $148,170118 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Insulin Lispro | $94 | $65,93770 claims |
| Boehringer IngelheimJardiance | $80 | $53,39571 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $42 | $36,73734 claims |
| AstraZenecaFarxiga | $348 | $29,16925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.
Other family in Gallipolis
- Suzanna DuncanGallipolis$45K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.